Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 14/20 | 0.64 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.53 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.42 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1829935 | 0.91 | MTOR (0.65) | MTORPIK3CDPIK3CAPIK3R1PIK3CG | |
| SCHEMBL1832656 | 0.91 | MTOR (0.75) | MTORPIK3CDPIK3CAPIK3R1PIK3CG | |
| SCHEMBL1832649 | 0.87 | MTOR (0.67) | MTORPIK3CDPIK3CAPIK3CGCYP3A4 | |
| SCHEMBL1830875 | 0.84 | MTOR (0.61) | MTORPIK3CDPIK3CAPIK3CGCYP3A4 | |
| SCHEMBL15196040 | 0.84 | PIK3CD (0.51) | MTORPIK3CDPIK3CAPIK3R1PIK3CG | |
| SCHEMBL15196082 | 0.82 | PIK3CD (0.49) | MTORPIK3CDPIK3CAPIK3R1PIK3CG | |
| SCHEMBL1831188 | 0.82 | MTOR (0.68) | MTORPIK3CAPIK3R1PIK3CGCYP3A4 | |
| SCHEMBL1831922 | 0.82 | MTOR (0.79) | MTORPIK3CAPIK3R1CYP3A4RPTOR | |
| SCHEMBL15190028 | 0.81 | MTOR (0.62) | MTORPIK3CDPIK3CAPIK3R1PIK3CG | |
| SCHEMBL1831860 | 0.80 | MTOR (0.75) | MTORPIK3CDPIK3CAPIK3R1PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318377-B1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-20120165313-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165313-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8163763-B2 | Pyrimidine compounds, compositions and methods of use | GENENTECH, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163763-B2 | Pyrimidine compounds, compositions and methods of use | GENENTECH, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100069357-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069357-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| WO-2010014939-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165313-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MTOR, TYMS, DTYMK | MTOR 1/4885PIK3CD 13/4885PIK3CA 4/4885 |
| US-20100069357-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MTOR, TYMS, DTYMK | MTOR 1/4885PIK3CD 13/4885PIK3CA 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.